PTP4A3 expression and survival outcomes were significantly correlated in AML(GSE12417-GPL96), BLCA (GSE5287 and GSE13507), glioblastoma (GSE7696), breast cancer (GSE9893, GSE9195 and GSE9195), eye cancer (GSE22138), MGH-glioma, non-small cell lung cancer (NSCLC) (GSE4716-GPL3696), ovarian cancer (GSE9891) and skin cancer (GSE19234) (Supplementary Figures 2A–L). Here, PTP4A3 is linked to central nervous system cancer.